ADHD:
Indications for: Methylphenidate Extended-Release
Attention deficit hyperactivity disorder.
Adults and Children:
Swallow whole. May use methylphenidate extended-release tabs in place of methylphenidate tabs when the 8-hr dose of methylphenidate extended-release corresponds to the titrated 8-hr dose of methylphenidate. Max 60mg daily.
Methylphenidate Extended-Release Contraindications:
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.
Boxed Warning:
Drug abuse and dependence.
Methylphenidate Extended-Release Warnings/Precautions:
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Methylphenidate Extended-Release Classification:
CNS stimulant.
Methylphenidate Extended-Release Interactions:
See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.
Adverse Reactions:
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.
How Supplied:
Tabs, ext-rel tabs, chew tabs—contact supplier; Oral soln—500mL
Sleep-wake disorders:
Indications for: Methylphenidate Extended-Release
Narcolepsy.
Adults and Children:
Swallow whole. May use methylphenidate extended-release tabs in place of methylphenidate tabs when the 8-hr dose of methylphenidate extended-release corresponds to the titrated 8-hr dose of methylphenidate. Max 60mg daily.
Methylphenidate Extended-Release Contraindications:
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.
Boxed Warning:
Drug abuse and dependence.
Methylphenidate Extended-Release Warnings/Precautions:
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Methylphenidate Extended-Release Classification:
CNS stimulant.
Methylphenidate Extended-Release Interactions:
See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.
Adverse Reactions:
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.
How Supplied:
Tabs, ext-rel tabs, chew tabs—contact supplier; Oral soln—500mL
